Synthesis and pharmacology of benzoxazines as highly selective antagonists at M4 muscarinic receptors

被引:82
作者
Böhme, TM
Augelli-Szafran, CE
Hallak, H
Pugsley, T
Serpa, K
Schwarz, RD
机构
[1] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Med Chem, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA
[3] Pfizer Global Res & Dev, Ann Arbor Labs, Dept CNS Pharmacol, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/jm011116o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously, we reported on PD 102807 (41) as being the most selective synthetic M-4 muscarinic antagonist identified to date. Synthesized analogues of 41 showed no improvement in affinity and selectivity at that time. However, several newly synthesized compounds exhibit a 7-fold higher affinity at M-4 receptors and demonstrate a selectivity of at least 100-fold over all other muscarinic receptor subtypes. For example, compound 28 showed an affinity of pK(i) = 9.00 at M-4 receptors and a selectivity of M-1/M-4 = 13 183-fold, M-2,/M-4 = 339-fold, M-3/M-4 = 151-fold, and M-5/M-4 = 11 220-fold. This high selectivity along with high affinity has not been reported for any synthetic muscarinic antagonist, nor for natural occurring M4 antagonists such as the M-4 selective Eastern Green Mamba venom MT3 (M4 pK(b) = 8.7, M-1/M-4 = 40-fold, M-2/M-4 greater than or equal to 500-fold, M-3/M-4 greater than or equal to 500-fold, and M-5/M-4 greater than or equal to 500-fold). Derivative 24, a compound with a high selectivity pattern as well, has been tested for in vivo efficacy. It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1017, an M-1/M-4 selective muscarinic agonist, in the mesolimbic region and striatum, which suggests that 24 is capable of crossing the blood-brain barrier and confirms the pharmacokinetic data obtained on this compound. This is evidence that suggests that agonist-induced increase in catecholamine synthesis observed in these regions is mediated by M-4 receptors.
引用
收藏
页码:3094 / 3102
页数:9
相关论文
共 32 条
[1]   EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON TURNOVER OF DOPAMINE IN CORPUS STRIATUM AND LIMBIC SYSTEM [J].
ANDEN, NE .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1974, 26 (09) :738-740
[2]   Identification and characterization of m4 selective muscarinic antagonists [J].
Augelli-Szafran, CE ;
Jaen, JC ;
Moreland, DW ;
Nelson, CB ;
Penvose-Yi, JR ;
Schwarz, RD .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (15) :1991-1996
[3]  
BERNARD V, 1992, J NEUROSCI, V12, P3591
[4]   ANTI-PARKINSON MEDICATION AND EXTRAPYRAMIDAL REACTIONS - STUDY OF TRIHEXYPHENIDYL [J].
BORDELEAU, JM ;
ALBERT, JM ;
HILLEL, J ;
TETREAULT, L .
CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL, 1967, 12 (06) :585-959
[5]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[6]  
BYMASTER FP, 1994, J PHARMACOL EXP THER, V269, P282
[7]  
CARLSSON A, 1975, J NEURAL TRANSM, V40, P99
[8]  
Caulfield MP, 1998, PHARMACOL REV, V50, P279
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   EFFECT OF M1-MUSCARINIC AND M2-MUSCARINIC DRUGS ON STRIATAL DOPAMINE RELEASE AND METABOLISM - AN IN-VIVO MICRODIALYSIS STUDY COMPARING NORMAL AND 6-HYDROXYDOPAMINE-LESIONED RATS [J].
DEKLIPPEL, N ;
SARRE, S ;
EBINGER, G ;
MICHOTTE, Y .
BRAIN RESEARCH, 1993, 630 (1-2) :57-64